• Humacyte will present coronary bypass research at the American Heart Association Scientific Sessions, Nov. 6-9, 2026, in Chicago.
• CEO Laura Niklason will discuss engineering the microenvironment to accelerate vascular regeneration on Nov. 7.
• A Nov. 7 presentation will outline the first-in-human Phase 2a study design for its investigational bioengineered coronary bypass vessel.
• Preclinical coronary bypass results from porcine and ovine models will be presented Nov. 8.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humacyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611030800PRIMZONEFULLFEED9868688) on November 03, 2026, and is solely responsible for the information contained therein.